GT
VTAE

Glenmede Trust’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Glenmede Trust’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,546
Closed -$138K – 2860
2015
Q3 		$138K Buy
+12,546
New +$133K ﹤0.01% 1292

Other funds holding VTAE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Glenmede Trust's VTAE Position: Q4 2015 in Review

Glenmede Trust sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2015, closing a stake of 12,546 shares — an estimated $138K sold.

Glenmede Trust first reported a position in VTAE in Q3 2015 and held it in 1 quarter. The position peaked at $138K in Q3 2015. 76 funds tracked by Wall St. Rank hold VTAE as of Q4 2015.

  • Glenmede Trust reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2015 after selling out during the quarter.
  • Glenmede Trust sold 12,546 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2015, an estimated $138K.
  • Glenmede Trust first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2015 and held it in 1 quarter.
  • Glenmede Trust's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $138K in Q3 2015.
  • 76 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.